147 related articles for article (PubMed ID: 34901149)
1. Overcome Chemoresistance: Biophysical and Structural Analysis of Synthetic FHIT-Derived Peptides.
Scala MC; Di Micco S; Lanzillotta D; Musella S; Di Sarno V; Parrino B; Casciofierro SM; Bifulco G; Trapasso F; Campiglia P; Sala M
Front Mol Biosci; 2021; 8():715263. PubMed ID: 34901149
[TBL] [Abstract][Full Text] [Related]
2. A Fhit-mimetic peptide suppresses annexin A4-mediated chemoresistance to paclitaxel in lung cancer cells.
Gaudio E; Paduano F; Ngankeu A; Ortuso F; Lovat F; Pinton S; D'Agostino S; Zanesi N; Aqeilan RI; Campiglia P; Novellino E; Alcaro S; Croce CM; Trapasso F
Oncotarget; 2016 May; 7(21):29927-36. PubMed ID: 27166255
[TBL] [Abstract][Full Text] [Related]
3. Fhit delocalizes annexin a4 from plasma membrane to cytosol and sensitizes lung cancer cells to paclitaxel.
Gaudio E; Paduano F; Spizzo R; Ngankeu A; Zanesi N; Gaspari M; Ortuso F; Lovat F; Rock J; Hill GA; Kaou M; Cuda G; Aqeilan RI; Alcaro S; Croce CM; Trapasso F
PLoS One; 2013; 8(11):e78610. PubMed ID: 24223161
[TBL] [Abstract][Full Text] [Related]
4. MAD analysis of FHIT, a putative human tumor suppressor from the HIT protein family.
Lima CD; D'Amico KL; Naday I; Rosenbaum G; Westbrook EM; Hendrickson WA
Structure; 1997 Jun; 5(6):763-74. PubMed ID: 9261067
[TBL] [Abstract][Full Text] [Related]
5. Corrigendum: Overcome Chemoresistance: Biophysical and Structural Analysis of Synthetic FHIT-Derived Peptides.
Scala MC; Di Micco S; Lanzillotta D; Musella S; Di Sarno V; Parrino B; Cascioferro SM; Bifulco G; Trapasso F; Campiglia P; Sala M
Front Mol Biosci; 2022; 9():915838. PubMed ID: 35573730
[TBL] [Abstract][Full Text] [Related]
6. In silico study of fragile histidine triad interaction domains with MDM2 and p53.
Eslamparast A; Ghahremani MH; Sardari S
Adv Biomed Res; 2014; 3():170. PubMed ID: 25221773
[TBL] [Abstract][Full Text] [Related]
7. Annexin A4 induces platinum resistance in a chloride-and calcium-dependent manner.
Morimoto A; Serada S; Enomoto T; Kim A; Matsuzaki S; Takahashi T; Ueda Y; Yoshino K; Fujita M; Fujimoto M; Kimura T; Naka T
Oncotarget; 2014 Sep; 5(17):7776-87. PubMed ID: 25277200
[TBL] [Abstract][Full Text] [Related]
8. Association of FHIT (fragile histidine triad), a candidate tumour suppressor gene, with the ubiquitin-conjugating enzyme hUBC9.
Shi Y; Zou M; Farid NR; Paterson MC
Biochem J; 2000 Dec; 352 Pt 2(Pt 2):443-8. PubMed ID: 11085938
[TBL] [Abstract][Full Text] [Related]
9. HIV-TAT-fused FHIT protein functions as a potential pro-apoptotic molecule in hepatocellular carcinoma cells.
Yu GR; Qin WW; Li JP; Hua W; Meng YL; Chen R; Yan B; Wang L; Zhang X; Jia LT; Zhao J; Zhang R; Yang AG
Biosci Rep; 2012 Jun; 32(3):271-9. PubMed ID: 21679157
[TBL] [Abstract][Full Text] [Related]
10. Fragile histidine triad (FHIT) gene abnormalities in lung cancer.
Zöchbauer-Müller S; Wistuba II; Minna JD; Gazdar AF
Clin Lung Cancer; 2000 Nov; 2(2):141-5. PubMed ID: 14731325
[TBL] [Abstract][Full Text] [Related]
11. Comparative genomic mapping of the bovine Fragile Histidine Triad (FHIT) tumour suppressor gene: characterization of a 2 Mb BAC contig covering the locus, complete annotation of the gene, analysis of cDNA and of physiological expression profiles.
Uboldi C; Guidi E; Roperto S; Russo V; Roperto F; Di Meo GP; Iannuzzi L; Floriot S; Boussaha M; Eggen A; Ferretti L
BMC Genomics; 2006 May; 7():123. PubMed ID: 16719907
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological significance of the fragile histidine triad transcription protein expression in laryngeal carcinogenesis.
Kitamura K; Hayashi K; Kobayashi R; Ishii H; Matsubayashi J; Matsumoto T; Suzuki M
Oncol Rep; 2008 Apr; 19(4):847-52. PubMed ID: 18357366
[TBL] [Abstract][Full Text] [Related]
13. Implication of mitochondrial involvement in apoptotic activity of fragile histidine triad gene: application of synchronous luminescence spectroscopy.
Askari MD; Vo-Dinh T
Biopolymers; 2004 Mar; 73(4):510-23. PubMed ID: 14991669
[TBL] [Abstract][Full Text] [Related]
14. Computational Survey of FHIT, A Putative Human Tumor Suppressor, Truncates Structure.
Eslamparast A; Ghahremani MH; Sardari S
Avicenna J Med Biotechnol; 2014 Apr; 6(2):64-71. PubMed ID: 24834308
[TBL] [Abstract][Full Text] [Related]
15. Expression and simple, one-step purification of fragile histidine triad (Fhit) tumor suppressor mutant forms in Escherichia coli and their interaction with protoporphyrin IX.
Zawacka-Pankau J; Podhajska AJ
Biotechnol Lett; 2007 Jun; 29(6):877-83. PubMed ID: 17310323
[TBL] [Abstract][Full Text] [Related]
16. Fragile histidine triad protein: structure, function, and its association with tumorogenesis.
Hassan MI; Naiyer A; Ahmad F
J Cancer Res Clin Oncol; 2010 Mar; 136(3):333-50. PubMed ID: 20033706
[TBL] [Abstract][Full Text] [Related]
17. Do FHIT gene alterations play a role in human solid tumors?
Silveira Zavalhia L; Weber Medeiros A; Oliveira Silva A; Vial Roehe A
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e214-e223. PubMed ID: 29516675
[TBL] [Abstract][Full Text] [Related]
18. Expression of fragile histidine triad in primary hepatocellular carcinoma and its relation with cell proliferation and apoptosis.
Nan KJ; Ruan ZP; Jing Z; Qin HX; Wang HY; Guo H; Xu R
World J Gastroenterol; 2005 Jan; 11(2):228-31. PubMed ID: 15633221
[TBL] [Abstract][Full Text] [Related]
19. The Fragile Histidine Triad gene and breast cancer.
Yang Q; Yoshimura G; Sakurai T; Kakudo K
Med Sci Monit; 2002 Jul; 8(7):RA140-4. PubMed ID: 12118213
[TBL] [Abstract][Full Text] [Related]
20. Correlation of fragile histidine triad (Fhit) protein structural features with effector interactions and biological functions.
Pichiorri F; Okumura H; Nakamura T; Garrison PN; Gasparini P; Suh SS; Druck T; McCorkell KA; Barnes LD; Croce CM; Huebner K
J Biol Chem; 2009 Jan; 284(2):1040-9. PubMed ID: 19004824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
